| Basics |
| Company: |
Bicara Therapeutics Inc. Common Stock |
| IPO Date: |
September 13, 2024 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$707.4M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.70 | 3.66%
|
| Avg Daily Range (30 D): |
$0.45 | 3.50%
|
| Avg Daily Range (90 D): |
$0.62 | 3.52%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.35M |
| Avg Daily Volume (30 D): |
.29M |
| Avg Daily Volume (90 D): |
.31M |
| Trade Size |
| Avg Trade Size (Sh.): |
75 |
| Avg Trade Size (Sh.) (30 D): |
70 |
| Avg Trade Size (Sh.) (90 D): |
67 |
| Institutional Trades |
| Total Inst.Trades: |
91 |
| Avg Inst. Trade: |
$1.9M |
| Avg Inst. Trade (30 D): |
$.72M |
| Avg Inst. Trade (90 D): |
$1.86M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.87M |
| Avg Closing Trade (30 D): |
$.58M |
| Avg Closing Trade (90 D): |
$3.43M |
| Avg Closing Volume: |
161.61K |
|
|
|
|
| Financials |
| |
TTM |
Q3 2024 |
Q2 2024 |
|
Basic EPS
|
|
$-1.6
|
|
|
Diluted EPS
|
|
$-1.6
|
|
|
Revenue
|
$
|
$ M
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -17.48M
|
$ -17.05M
|
|
Operating Income / Loss
|
$
|
$ -20.63M
|
$
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$
|
$
|
|
PE Ratio
|
|
|
|
|
